| Literature DB >> 33376684 |
Huda A Rasheed1, Marwa S Al-Naimi1, Nawar R Hussien1, Naseer A Al-Harchan1, Hayder M Al-Kuraishy1, Ali I Al-Gareeb1.
Abstract
OBJECTIVE: To evaluate the nephroprotective effect of lycopene (LPN) in acute kidney injury (AKI) regarding the oxidative stress (OS).Entities:
Keywords: Acute kidney injury; diclofenac; lycopene
Year: 2020 PMID: 33376684 PMCID: PMC7759068 DOI: 10.4103/IJCIIS.IJCIIS_113_19
Source DB: PubMed Journal: Int J Crit Illn Inj Sci ISSN: 2229-5151
Figure 1Consort flow diagram of the present study
Anthropometric and biochemical changes in diclofenac-induced acute kidney injury compared with control
| Parameters | Control ( | AKI ( | Differences | 95% CI | |
|---|---|---|---|---|---|
| BMI (g/cm2) | 0.55±0.1 | 0.61±0.1 | 0.110 | 0.01–0.20 | 0.02* |
| CreSerum (mg/dL) | 0.88±0.1 | 1.92±0.2 | 1.040 | 0.89–1.18 | 0.001# |
| Blood urea (mg/dL) | 39.73±7.96 | 57.28±9.61 | 17.550 | 9.25–25.84 | 0.0001# |
| eGFR (ml/min/1.73) | 15.88±3.75 | 11.69±2.64 | −4.190 | −8.15–0.22 | 0.03* |
| KIM (pg/mL) | 88.68±12.39 | 122.78±18.45 | 34.100 | 19.33–48.86 | 0.0001# |
| NGAL (pg/mL) | 14.93±4.61 | 22.83±5.63 | 7.900 | 0.06–9.73 | 0.001# |
| MDA (ng/mL) | 240.52±11.72 | 298.61±16.72 | 58.090 | 44.52–71.65 | 0.0001# |
| SOD (pg/mL) | 45.78±9.69 | 22.78±7.56 | 23.000 | −31.16–14.83 | 0.0001# |
Data presented as mean±SD. *P<0.05, #P<0.01. BMI: Body mass index, eGFR: Estimated glomerular filtration rate, KIM-1: Kidney injury molecules, NGAL: Neutrophil gelatinase-associated lipocalin, MDA: Malondialdehyde, SOD: Superoxide dismutase, SD: Standard deviation, CreSerum: Serum creatinine, AKI: Acute kidney injury, CI: Confidence interval
Effects of lycopene on the anthropometric and biochemical variables in rat with acute kidney injury
| Parameters | AKI ( | Lycopene ( | Differences | 95% CI | |
|---|---|---|---|---|---|
| BMI (g/cm2) | 0.61±0.1 | 0.58±0.02 | −0.030 | −0.12–0.06 | 0.51 |
| CreSerum (mg/dL) | 1.92±0.2 | 1.043±0.2 | −0.877 | −1.06–0.68 | 0.001 |
| Blood urea (mg/dL) | 57.28±9.61 | 44.84±8.66 | −12.440 | −21.03–3.84 | 0.007 |
| eGFR (ml/min/1.73) | 11.69±2.64 | 14.81±3.21 | 3.120 | 0.35–5.88 | 0.02 |
| KIM (pg/mL) | 122.78±18.45 | 96.64±13.55 | −26.140 | −41.34–10.93 | 0.002 |
| NGAL (pg/mL) | 22.83±5.63 | 15.59±6.29 | −7.240 | −12.84–1.63 | 0.01 |
| MDA (ng/mL) | 298.61±16.72 | 250.74±12.47 | −47.870 | −16.72–34.01 | 0.001 |
| SOD (pg/mL) | 22.78±7.56 | 33.86±8.61 | 11.080 | 3.46–18.69 | 0.006 |
Data presented as mean±SD. BMI: Body mass index, eGFR: Estimated glomerular filtration rate, KIM-1: Kidney injury molecules, NGAL: Neutrophil gelatinase-associated lipocalin, MDA: Malondialdehyde, SOD: Superoxide dismutase, SD: Standard deviation, CreSerum: Serum creatinine, AKI: Acute kidney injury, CI: Confidence interval
Figure 2Effect of lycopene on malondialdehyde/superoxide dismutase ratio in acute kidney injury
Correlations of malondialdehyde/superoxide dismutase ratio with anthropometric and biochemical variables
| Parameters | AKI ( | Lycopene I ( | ||
|---|---|---|---|---|
| BMI (g/cm2) | 0.44 | 0.20 | 0.46 | 0.18 |
| CreSerum (mg/dL) | 0.67 | 0.03 | 0.56 | 0.09 |
| Blood urea (mg/dL) | 0.72 | 0.01 | 0.48 | 0.16 |
| eGFR (ml/min/1.73) | 0.64 | 0.04 | 0.60 | 0.06 |
| KIM (pg/mL) | 0.86 | 0.001 | 0.70 | 0.02 |
| NGAL (pg/mL) | 0.75 | 0.01 | 0.68 | 0.03 |
| MDA (ng/mL) | 0.83 | 0.002 | 0.65 | 0.04 |
| SOD (pg/mL) | −0.87 | 0.001 | −0.80 | 0.005 |
Data presented as mean±SD. BMI: Body mass index, eGFR: Estimated glomerular filtration rate, KIM-1: Kidney injury molecules, NGAL: Neutrophil gelatinase-associated lipocalin, MDA: Malondialdehyde, SOD: Superoxide dismutase, SD: Standard deviation, CreSerum: Serum creatinine, AKI: Acute kidney injury